Brief: Marker Therapeutics Awarded $2 Mln Grant From NIH
12/08/2024 12:53
Aug 12 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS AWARDED $2 MILLION GRANT FROM NIH IN
SUPPORT
OF PHASE 1 STUDY INVESTIGATING MT-601 IN CAR-RELAPSED PATIENTS
WITH NON-HODGKIN’S LYMPHOMA
Source text for Eikon: ID:nGNX3V11Wp
Further company coverage: MRKR.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79